Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model
Tóm tắt
Studies have shown that dipeptidyl peptidase-4 (DPP4) inhibitors stimulate insulin secretion and increase beta cell mass in rodents. However, in these models hyperglycaemia has been induced early on in life and the treatment periods have been short. To explore the long-term effects of DPP4 inhibition on insulin secretion and beta cell mass, we have generated a high-fat diet (HFD)-induced-obesity model in mice of advanced age (10 months old). After 1 month of HFD alone, the mice were given the DPP4 inhibitor vildagliptin for a further 11 months. At multiple time points throughout the study, OGTTs were performed and beta cell area and long-term survival were evaluated. Beta cell function and glucose tolerance were significantly improved by vildagliptin with both diets. In contrast, in spite of the long treatment period, beta cell area was not significantly different between vildagliptin-treated mice and controls. Mice of advanced age chronically fed an HFD displayed clear and extensive pancreatic inflammation and peri-insulitis, mainly formed by CD3-positive T cells, which were completely prevented by vildagliptin treatment. Chronic vildagliptin treatment also improved survival rates for HFD-fed mice. In a unique advanced-aged HFD-induced-obesity mouse model, insulin secretion was improved and the extensive peri-insulitis prevented by chronic DPP4 inhibition. The improved survival rates for obese mice chronically treated with vildagliptin suggest that chronic DPP4 inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.
Tài liệu tham khảo
Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC (2006) Relationship between beta cell mass and fasting blood glucose concentration in humans. Diabetes Care 29:717–718
Ahren B (2011) The future of incretin-based therapy: novel avenues—novel targets. Diabetes Obes Metab 13(Suppl 1):158–166
Mu J, Woods J, Zhou YP et al (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695–1704
Duttaroy A, Voelker F, Merriam K et al (2011) The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 650:703–707
Takeda Y, Fujita Y, Honjo J et al (2012) Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55:404–412
Furuta Y, Horiguchi M, Sugaru E et al (2010) Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta cell damage in diabetic mice. Diabetes Obes Metab 12:421–430
Mu J, Petrov A, Eiermann GJ et al (2009) Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 623:148–154
Zhang X, Wang Z, Huang Y, Wang J (2011) Effects of chronic administration of alogliptin on the development of diabetes and beta cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metab 13:337–347
Muhlhausler BS (2009) Nutritional models of type 2 diabetes mellitus. Meth Mol Biol 560:19–36
Koopman RJ, Mainous AG 3rd, Diaz VA, Geesey ME (2005) Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med 3:60–63
Ahren J, Ahren B, Wierup N (2010) Increased beta cell volume in mice fed a high-fat diet: a dynamic study over 12 months. Islets 2:353–356
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta cell deficit and increased beta cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110
Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE (2011) Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 13:775–783
Myrsen U, Keymeulen B, Pipeleers DG, Sundler F (1996) Beta cells are important for islet innervation: evidence from purified rat islet-cell grafts. Diabetologia 39:54–59
Aoki CA, Borchers AT, Ridgway WM, Keen CL, Ansari AA, Gershwin ME (2005) NOD mice and autoimmunity. Autoimmun Rev 4:373–379
Henry RR (1998) Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 105:20S–26S
Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R (2003) The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 52:1475–1484
Blackwell BN, Bucci TJ, Hart RW, Turturro A (1995) Longevity, body weight, and neoplasia in ad libitum-fed and diet-restricted C57BL6 mice fed NIH-31 open formula diet. Toxicol Pathol 23:570–582
Miura K, Kitahara Y, Yamagishi S (2010) Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. Horm Metab Res 42:731–735
Inaba W, Mizukami H, Kamata K, Takahashi K, Tsuboi K, Yagihashi S (2012) Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol 691:297–306
Reimer MK, Holst JJ, Ahren B (2002) Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717–727
Ahren B, Foley JE (2008) The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl (159):8–14
Foley JE, Bunck MC, Moller-Goede DL et al (2011) Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54:1985–1991
Cnop M, Hughes SJ, Igoillo-Esteve M et al (2010) The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 53:321–330
Rankin MM, Kushner JA (2009) Adaptive beta cell proliferation is severely restricted with advanced age. Diabetes 58:1365–1372
Tschen SI, Dhawan S, Gurlo T, Bhushan A (2009) Age-dependent decline in beta cell proliferation restricts the capacity of beta cell regeneration in mice. Diabetes 58:1312–1320
Bonner-Weir S, Trent DF, Weir GC (1983) Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71:1544–1553
Rankin MM, King KB, Kim JJ, Tu JX, Li C, Kushner JA (2012) New B cells are not generated by prolonged administration of incretin-based therapies (exendin-4 or sitagliptin) in adult mouse pancreas. Diabetes 61:LB34
Giarratana N, Penna G, Adorini L (2007) Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Meth Mol Biol 380:285–311
Dobrian AD, Ma Q, Lindsay JW et al (2011) Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 300:E410–E421
Ferreira L, Teixeira-de-Lemos E, Pinto F et al (2010) Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediat Inflamm 2010:592760
Kim SJ, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T cell modulation. Diabetes 58:641–651
Tian L, Gao J, Hao J et al (2010) Reversal of new-onset diabetes through modulating inflammation and stimulating beta cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151:3049–3060
Morimoto C, Schlossman SF (1998) The structure and function of CD26 in the T cell immune response. Immunol Rev 161:55–70
Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408:239–247
Leibowitz G, Bachar E, Shaked M et al (2010) Glucose regulation of beta cell stress in type 2 diabetes. Diabetes Obes Metab 12(Suppl 2):66–75
Rizzo MR, Barbieri M, Marfella R, Paolisso G (2012) Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35:2076–2082